Plozasiran not checked

Arrowhead · ARO-APOC3

FollowEvery change as it happens, and a Monday email
Stage
in the US · approved in the EU
Next date
Phase 3 trial completes
Trials
3 active
11 in total · 8 in the EU
Targets
 

What this is

How it works
A short strand of RNA that switches off one gene, so the body makes less of one protein.-siran: small interfering RNA WHO name stem
Tested for
Hypertriglyceridemia, Severe Hypertriglyceridemia
Main trialPhase 3
“This is an open-label study to be conducted in adults with hypertriglyceridemia (HTG) and severe hypertriglyceridemia (SHTG). Each participant must have completed all required visits per protocol in the parent study AROAPOC3-2003 (USA and Canada participants only; NCT# 05413135), AROAPOC3-3001(Canada and Japan participants only; NCT05089084), AROAPOC3-3003 (NCT06347003), AROAPOC3-3004 (NCT06347016) or AROAPOC3-3009 (Argentina, Italy, South Africa, and Spain; NCT06347133). Subjects who previously met all eligibility requirements for AROAPOC3-3003 or AROAPOC3-3004 and were not permitted to…”In the company’s words, NCT06822790 on ClinicalTrials.gov
Other names
ARO-APOC3

Other drugs for Hypertriglyceridemia

All 15 drugs for Hypertriglyceridemia

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials11

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting Jul 2028 Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
Phase 3Recruiting Mar 2029 Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
Phase 3Completed 29 Apr 2024 Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)
Phase 3Completed 1 Jun 2026 Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
Phase 3Completed 12 Jun 2026 Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
Phase 3Completed 17 Jun 2026 Study of Plozasiran in Adults With Severe Hypertriglyceridemia
Phase 2Completed 10 Feb 2023 Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia
Phase 2Completed 9 Mar 2023 Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia
Phase 2Completed 22 Sep 2025 Study of ARO-APOC3 in Adults With Dyslipidemia
Phase 1Completed 11 Feb 2021 Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS)
Phase 3Authorised not given Open-Label Study to Evaluate the Activity, Pharmacokinetics, Pharmacodynamics, And Safety of Plozasiran in Adolescents (Age 12 to <18 Years) With Familial Chylomicronemia Syndrome
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Plozasiran

Following is part of Solo: you see every change to Plozasiran the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in